Vaccinex Inc
-0.0005 (-0.08%)
Volume 88,544
Bid Price 0.565
Ask Price 0.64
News -
Day High 0.63


52 Week Range


Day Low 0.5711
Company Name Stock Ticker Symbol Market Type
Vaccinex Inc VCNX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0005 -0.08% 0.595 17:13:48
Open Price Low Price High Price Close Price Prev Close
0.60 0.5711 0.63 0.595 0.5955
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
243 88,544 $ 0.594524 $ 52,642 - 0.41 - 2.28
Last Trade Time Type Quantity Stock Price Currency
16:00:01 30 $ 0.5955 USD


Draw Mode:

Vaccinex Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 29.68M 49.88M 30.21M $ 900.00k $ - -0.79 -1.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 5.56M 0.70%

more financials information »

Vaccinex News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical VCNX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.59150.6350.560.59173360,6120.00350.59%
1 Month0.620.6750.5570.610401546,698-0.025-4.03%
3 Months0.570.7798990.410.612367256,1140.0254.39%
6 Months1.061.500.410.818643597,793-0.465-43.87%
1 Year1.132.280.411.34189,516-0.535-47.35%
3 Years7.3211.000.413.75813,987-6.73-91.87%
5 Years12.0012.230.413.78553,250-11.41-95.04%

Vaccinex Description

Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb. The firm generates revenue from collaborative research, license, development and commercialization agreements.